http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9388224-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f79749e86afce9444a364ab60ca3584 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2015-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b7e0c55131476e89aaed3b358adfd80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15c289952dafe0a93a6a56497ce82022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff40e95ed1542bf162e1fbadc55e055d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2690c4f33ab9986b37cf445f7bec64a8 |
| publicationDate | 2016-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9388224-B2 |
| titleOfInvention | Compositions for preserving insulin-producing cells and insulin production and treating diabetes |
| abstract | Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.1 can result in lowering of fasting blood glucose levels and may ameliorate (e.g., reduce, eliminate) insulin resistance, the compositions, methods and cells described herein can also be used for treating Type 2 diabetes (T2D). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10272133-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11571455-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016354431-A1 |
| priorityDate | 2011-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 491.